Andy Weiskopf
About Andy Weiskopf
Andy Weiskopf serves as the Vice President of Cmc Regulatory Affairs at Sana Biotechnology, Inc., a position he has held since 2019. He has extensive experience in regulatory affairs and technical development, having worked in various roles at Biogen and other institutions over a career spanning more than two decades.
Current Role at Sana Biotechnology
Andy Weiskopf serves as the Vice President of Cmc Regulatory Affairs at Sana Biotechnology, Inc. since 2019. In this position, he is responsible for overseeing regulatory strategies and compliance related to Chemistry, Manufacturing, and Controls (CMC) within the organization. His role involves ensuring that the company's products meet regulatory requirements and standards, facilitating the development of innovative therapies.
Previous Experience at Biogen
Andy Weiskopf held multiple positions at Biogen, contributing significantly to the company's regulatory and technical development efforts. He served as Director of Global Regulatory Affairs Cmc, Gene Therapy from 2016 to 2019, and prior to that, he was the Director of Technical Development from 2013 to 2016. Additionally, he worked as Associate Director of Analytical Development from 2010 to 2013 and as Senior Scientist, Analytical Development-cmc Lead from 2007 to 2010. His extensive experience at Biogen focused on advancing regulatory compliance and analytical development.
Educational Background
Andy Weiskopf began his academic journey at Brandeis University, where he studied from 1989 to 1993. He then pursued further education at Northeastern University, completing his graduate studies from 1993 to 1998. His educational background provided a strong foundation for his career in regulatory affairs and technical development in the biotechnology sector.
Career at Cetek Corporation
Before joining Biogen, Andy Weiskopf worked at Cetek Corporation as a Senior Scientist from 1998 to 2007. During his nine years at Cetek, he focused on scientific research and development, contributing to the company's projects and initiatives in the biotechnology field.